Pharmadrug Stock EBITDA
| LMLLF Stock | USD 0.01 0.0006 5.83% |
Pharmadrug fundamentals help investors to digest information that contributes to Pharmadrug's financial success or failures. It also enables traders to predict the movement of Pharmadrug Pink Sheet. The fundamental analysis module provides a way to measure Pharmadrug's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmadrug pink sheet.
Pharmadrug |
Pharmadrug Company EBITDA Analysis
Pharmadrug's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Pharmadrug EBITDA | (5.27 M) |
Most of Pharmadrug's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmadrug is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Pharmadrug reported earnings before interest,tax, depreciation and amortization of (5.27 Million). This is 100.6% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.14% higher than that of the company.
Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Pharmadrug Fundamentals
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.08) % | |||
| Current Valuation | 4.43 M | |||
| Shares Outstanding | 355.63 M | |||
| Shares Owned By Insiders | 1.88 % | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 7.86 X | |||
| Revenue | 494.99 K | |||
| Gross Profit | 182.04 K | |||
| EBITDA | (5.27 M) | |||
| Net Income | (5.63 M) | |||
| Cash And Equivalents | 126.38 K | |||
| Total Debt | 786.37 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 2.69 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (4.13 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 2.94 | |||
| Market Capitalization | 3.97 M | |||
| Total Asset | 19.52 M | |||
| Z Score | 3.0 | |||
| Net Asset | 19.52 M |
About Pharmadrug Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmadrug's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmadrug using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmadrug based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmadrug Pink Sheet
Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.